Search PubMed⌕ Search

Biomedical subjects

R Rütter

Publications and source records attributed to R Rütter.

7 recordsLinked to original sources
PubMed1987

Increased growth stimulation of human vascular cells by serum from patients with primary hyper-LDL-cholesterolemia.

Premature atherosclerosis in hypercholesterolemic patients may be due, in part, to increased growth of vascular cells. Therefore, the growth stimulating effect of serum and serum fractions from patients with primary hyper-LDL-cholesterolemia (LDL-cholesterol: 7.5 +/- 1.7 mmol/l) and from healthy subjects on human arterial smooth muscle cells and fibroblasts has been investigated over 5-7 days in culture. Human hypercholesterolemic sera increased the growth of both cell types up to a mean of 133% compared with normal sera (100%) (P less than 0.001). Removal of the dialyzable serum fraction (m.w. less than 3,500 daltons) reduced the growth effect of the hypercholesterolemic sera by 32% (P less than 0.001) and of the normal sera by 11% (P less than 0.01). Readdition of the hypercholesterolemic serum dialysate to its dialyzed serum restored completely the original growth effect. There was no significant difference in growth stimulation between the dialyzed hypercholesterolemic and normal sera excluding a major additional growth effect by LDL-cholesterol. The low molecular weight growth factor(s) of hypercholesterolemic serum (m.w. less than 3,500 daltons) showed a linear dependence of growth stimulation over a 20-fold concentration range. Increased amounts of this factor(s) might easily penetrate the arterial wall, thus contributing to atherogenesis.

Adult↗
PubMed1987

Vascular growth factors and the development of macrovascular disease in diabetes mellitus.

The pathogenesis of macrovascular disease in diabetes mellitus is still incompletely understood. Within the various pathomechanisms abnormal growth of vascular cells is well established as an intrinsic part of the angiopathic process. In this regard, there are different groups of vascular growth factors that are of potential relevance for the development of macrovascular disease in diabetes : hormones, locally released growth factors of platelet and of arterial wall cell origin. The following hormones whose blood levels could increase under various conditions in diabetes have to be considered : growth hormone, insulin-like growth factor I and II and insulin. Human platelets contain at least eight growth peptides or proteins that all stimulate in vitro growth of arterial wall cells : platelet-derived-, epidermal-, fibroblast-, diabetic serum-, endothelial- and transforming growth factor, vascular endothelial cell proliferation factor and platelet-derived endothelial cell mitogen. In serum and plasma from type II diabetics only the diabetic serum growth factor has been shown to be increased. Platelets from type I and II diabetic patients contain increased growth stimulating activity. This increased growth activity returned to normal levels in both types of diabetes after strict metabolic control. Arterial endothelial and smooth muscle cells, fibroblasts and monocyte/macrophages of different species release at least in culture a variety of growth factors that could participate in an autocrine or paracrine manner in the growth regulation of the arterial wall. Diabetes may affect the release of these factors, but direct evidence to which degree this would contribute to the development of macrovascular disease is lacking.(ABSTRACT TRUNCATED AT 250 WORDS)

Animals↗
PubMed1985

Sera from type 2 (non-insulin-dependent) diabetic and healthy subjects contain different amounts of a very low molecular weight growth peptide for vascular cells.

Diabetic angiopathy may be due, in part, to increased growth in vascular cells. We have investigated serum growth factors in Type 2 (non-insulin-dependent) diabetic and healthy subjects and their effect on cultured human arterial smooth muscle cells and fibroblasts. Removal of the dialyzable serum fraction (mol. wt. less than 12,000) reduced the growth effect of the diabetic sera by 37% (2p less than 0.005) and of the non-diabetic sera by only 8% (2p less than 0.01). In contrast, there was no difference in growth stimulation between the dialyzed diabetic or non-diabetic sera. Complete recovery of the dialyzable serum growth fraction was also obtained at a mol. wt. below 3,500. Ten times the concentration of the low molecular weight growth factor (mol. wt. less than 3,500) from diabetic sera stimulated growth of fibroblasts or arterial smooth muscle cells by a mean of 243% or 174% and from non-diabetic sera by a mean of 146% or 137%, respectively (2p less than 0.01). The growth stimulating potency of this serum fraction (mol. wt. less than 3,500) contained in 10% diabetic sera, was two to ten times higher than that of human growth hormone or insulin, added in amounts equivalent to 10% or physiological serum concentrations. This diabetic serum growth factor was further characterized by: (1) linear dependence of growth stimulation over a concentration range of twenty times and by (2) reduction of the growth stimulating activity to control levels by pretreatment: (a) at 95 degrees C for 30 min, or (b) with two different proteases: Serva pronase E (Streptomyceus griseus) or Calbiochem protease (Subtilisin calsberg).(ABSTRACT TRUNCATED AT 250 WORDS)

Adult↗
PubMed1985

Vascular growth factors and the development of macrovascular disease in diabetes mellitus.

There are two different classes of humoral growth factors for arterial smooth muscle and endothelial cells that age of potential relevance for the development of macrovascular disease inn diabetes mellitus: hormones (growth hormone, insulin like growth factor I and II, insulin) and locally released growth factors of platelet origin. The following hormones have to be considered: Increased growth hormone plasma levels might contribute to macrovascular disease, but its actual relevance remains to be determined. Insulin like growth factor I and II are present in vivo and stimulate growth of vascular cells in vitro but their relevance for macrovascular disease in diabetes is unproven. To insulin, see Dr. Stout's paper. Human platelets contain at least six growth peptides or proteins that all stimulate in vitro growth of arterial wall cells: platelet derived growth factor, epidermal growth factor, platelet derived endothelial cell mitogen, endothelial growth factor, diabetic serum growth factor (DSGF), transforming growth factor-beta. As their plasma concentrations have not been shown to be increased in diabetes increased local availability at sites of stimulated platelet aggregation has been postulated. Therefore, their relevance for macrovascular disease i diabetics is based mainly on circumstantial evidence. The concentration of DSGF of platelet origin depends on the metabolic control: it increases in vivo in poorly controlled diabetics and is normalized after 2-3 weeks of good metabolic control in the same diabetic patient. The growth potency of DSGF from poorly controlled diabetics is greater than that of physiological amounts of insulin or growth hormone.(ABSTRACT TRUNCATED AT 250 WORDS)

Blood Platelets↗